Skip to main content

Advertisement

SpringerLink
Log in

The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Renal-cell carcinoma (RCC) is susceptible to immune therapy including the use of the nonmyeloablative allogeneic transplantation (NST). However, NST can produce severe toxicity, might not be appropriate for many patients with metastatic RCC. Other novel allogeneic immunotherapies are designed to induce an autologous immune response directed against the malignancy. In single-arm phase II trials, thalidomide has demonstrated a modest activity in the treatment of advanced RCC. Here we present a case report in which a patient with advanced RCC in the absence of transplant conditioning, that was receiving thalidomide, was infused with partially HLA-matched irradiated allogeneic lymphocytes. In this patient a complete response with weak acute graft-versus-host disease (GVHD) was observed. No evidence of the disease was present over the subsequent 36 months survival of the patient, suggesting that the infusions may have played a major role in the antineoplastic effect. A potential mechanism of this protocol may involve a host-versus-graft reactions-mediated antitumor effect against the malignancy. In addition, the present results suggest that a combination protocol with alternate treatment (e.g., chemotherapy) schedules merit further investigation in the management of various malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–75.

    Article  CAS  PubMed  Google Scholar 

  2. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343(11):750–8.

    Article  CAS  PubMed  Google Scholar 

  3. Bregni M, Ueno NT, Childs R. The second international meeting on allogeneic transplantation in solid tumors. Bone Marrow Transplant. 2006;38(8):527–37.

    Article  CAS  PubMed  Google Scholar 

  4. Lin H, Ye YB, Li XF, et al. Graft-versus-tumor (GVT) effect induced by haploidentical transplantation in mice. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kanfu. 2008;12(3):456–60.

    Google Scholar 

  5. Mattsson J, Uzunel M, Remberger M, et al. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation. 2001;71(3):433–9.

    Article  CAS  PubMed  Google Scholar 

  6. Strair RK, Schaar D, Medina D, et al. Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. J Clin Oncol. 2003;21(20):3785–91.

    Article  PubMed  Google Scholar 

  7. Porter DL, Connors JM, Van Deerlin VM, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999;17(4):1234.

    CAS  PubMed  Google Scholar 

  8. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003;9(5):320–9.

    Article  PubMed  Google Scholar 

  9. Li X, Liu X, Wang J, et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 2003;23(3B):2481–7.

    CAS  PubMed  Google Scholar 

  10. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699–703.

    Article  CAS  PubMed  Google Scholar 

  11. Lee CP, Patel PM, Selby PJ, et al. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(6):898–903.

    Article  CAS  PubMed  Google Scholar 

  12. Srinivas S, Guardino AE. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU Int. 2005;96(4):536–9.

    Article  CAS  PubMed  Google Scholar 

  13. Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol. 2003;46(Suppl):S59–65.

    Article  PubMed  Google Scholar 

  14. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.

    Article  CAS  PubMed  Google Scholar 

  15. Amato RJ, Morgan M, Rawat A. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer. 2006;106(7):1498–506.

    Article  CAS  PubMed  Google Scholar 

  16. Schrader AJ, Heidenreich A, Hegele A, et al. Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma. Anticancer Drugs. 2005;16(5):581–5.

    Article  CAS  PubMed  Google Scholar 

  17. Huss R, Deeg HJ, Gooley T, et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant. 1996;18(4):767–76.

    CAS  PubMed  Google Scholar 

  18. Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330(2):100–6.

    Article  CAS  PubMed  Google Scholar 

  19. Kraus AB, Shaffer J, Toh HC, et al. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol. 2003;31(7):609–21.

    Article  PubMed  Google Scholar 

  20. Su X, Guo S, Zhou C, et al. A simple and effective method for cancer immunotherapy by inactivated allogeneic leukocytes infusion. Int J Cancer. 2009;124(5):1142–51.

    Article  CAS  PubMed  Google Scholar 

  21. Rubio MT, Kim YM, Sachs T, et al. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood. 2003;102(6):2300–7.

    Article  CAS  PubMed  Google Scholar 

  22. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  23. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    Article  CAS  PubMed  Google Scholar 

  24. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  25. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34.

    Article  CAS  PubMed  Google Scholar 

  26. Lin RB, Fan NF, Guo ZQ, et al. A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. J Chemother. 2008;20(6):744–8.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Project supported by the Medical Innovation Foundation of Fujian Province (No.2007-CX-3).

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Fujian Provincial Tumor Hospital, Fujian Medical University, Fuzhou, 350014, People’s Republic of China

    Qiang Chen, Rong-Bo Lin, Nan-Feng Fan, Zeng-Qing Guo & Xiao-Jie Wang

  2. Laboratory of Immuno-Oncology, Fujian Provincial Tumor Hospital, Fujian Medical University, Fuzhou, 350014, People’s Republic of China

    Qiang Chen, Yun-Bin Ye, Zhi-Feng Zhou, Min-Shui Chen, Shu-Pin Chen & Jie-Yu Li

Authors
  1. Qiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rong-Bo Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun-Bin Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nan-Feng Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zeng-Qing Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhi-Feng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao-Jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Min-Shui Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shu-Pin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jie-Yu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiang Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Q., Lin, RB., Ye, YB. et al. The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. Med Oncol 27, 554–558 (2010). https://doi.org/10.1007/s12032-009-9250-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9250-8

Keywords

Search

Navigation